Wuxi AppTec Reports Surge in First-Half Earnings Amid US Scrutiny

POLICY WIRE — Shanghai, China — Wuxi AppTec, Asia’s largest provider of contract pharmaceutical research, has reported a significant surge in net income for the first half of the year. The Shanghai-based company posted net income of 11.08 billion yuan (US$1.64 billion), marking a 33.7% increase from the same period last year. This robust performance surpassed market expectations, driven by strong demand for weight-loss and diabetes drugs, as well as gains in its US business.

The interim net profit attributable to the owners of the company advanced by 33.7% to 11.08 billion yuan from a year earlier. This growth surpassed the Bloomberg mean consensus estimate, which was derived from a pool of 25 analysts. The company’s financial results come amid increased scrutiny from US regulators, highlighting the challenges and opportunities within the pharmaceutical research sector.

Wuxi AppTec’s strong performance is attributed to the rising demand for drugs aimed at treating weight-loss and diabetes, which have seen increased interest and investment in recent years. the company’s US operations have contributed to the overall growth, despite the regulatory pressures.

Reporting by Policy-Wire (PW)